Literature DB >> 10682969

Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans.

M H Kim1, M C Seong, N H Kwak, J S Yoo, W Huh, T G Kim, H Han.   

Abstract

PURPOSE: To study the distribution of human leukocyte antigen HLA-A/B antigens and HLA-DR/-DQ/-DP alleles and to investigate the immunogenetic background of Korean patients with Vogt-Koyanagi-Harada (VKH) syndrome and clinical course with different types of HLA.
METHODS: Human leukocyte antigen typings were performed in 18 Korean patients with VKH syndrome and in 128 healthy control subjects. HLA-A/B loci serologic typing was performed according to the standard microlymphocytotoxicity technique. DNA was extracted through the salting out method, and HLA-DR phenotyping and HLA-DR4, HLA-DQ, and HLA-DP subtyping were performed with the polymerase chain reaction-sequence specific oligonucleotide probe (PCR-SSOP) method.
RESULTS: Among HLA-A/B antigens typed by the standard microlymphocytotoxicity method, the frequencies of HLA-A31 (RR = 6.1, P<1x10(-2)) and HLA-B55 (RR = 15.8, P<.05) were significantly increased in the patient group compared with the control group. Among HLA-DR/-DQ/-DP alleles subtyped by DNA methods, the frequencies of HLA-DRB1*04 (RR = 45.1, P<1x10(-7)) and HLA-DRB1*07 (RR = 3.2, P<.05) were significantly increased. However, significant decreases in HLA-DRB1*08 (RR = .1, P<.05), HLA-DRB1*13 (RR = .1, P<.05), and HLA-DRB1*14 (RR = .1, P<.05) frequencies were observed. The result of HLA-DR, HLA-DQ, and HLA-DP subtyping showed the significant increase in DRB1*0405 (RR = 45.1, P<1x10(-7)), DQA1*0302 (RR = 12.0, P<1x10(-4)), DQB1*0303 (RR = 5.0, P<1x10(-2)), DQB1*0401 (RR = 18.9, P<1x 10-6), and DPB1*0501 (RR = 3.8, P<.05). However, significant decreases in DQA1*0101 (RR = .1, P< .05), DQA10102 (RR = .1, P<1x10(-2)), DQA1*0103 (RR = .1, P<.05), DQA1*0501 (RR = .1, P<1x10(-2)), DQB1*0301 (RR = .1, P<.05), DQB1*0601 (RR = .1, P<.05), DPB1*0201 (RR = .3, P<.05), and DPB1*0401 (RR = .1, P<.05) frequencies were also observed. In patients with DRB1*0405 itself or HLA-DRB1*0405-DQA1*0302-DQB1*0401 haplotype, a reduction in visual acuity and ocular complications was common.
CONCLUSIONS: These results suggest that HLA-DRB1*0405 itself or HLA-DRB1*0405-DQA1*0302-DQB1*0401 haplotype is greatly increased and may play the most important role in the development and the clinical course of VKH syndrome in Korean patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10682969     DOI: 10.1016/s0002-9394(99)00434-1

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  23 in total

1.  Altered gut microbiome composition in patients with Vogt-Koyanagi-Harada disease.

Authors:  Zi Ye; Chunyan Wu; Ni Zhang; Liping Du; Qingfeng Cao; Xinyue Huang; Jihong Tang; Qingfeng Wang; Fuzhen Li; Chunjiang Zhou; Qian Xu; Xiao Xiong; Aize Kijlstra; Nan Qin; Peizeng Yang
Journal:  Gut Microbes       Date:  2020-01-13

Review 2.  A look at autoimmunity and inflammation in the eye.

Authors:  Rachel R Caspi
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

3.  Uveitis-associated epitopes of retinal antigens are pathogenic in the humanized mouse model of uveitis and identify autoaggressive T cells.

Authors:  Mary J Mattapallil; Phyllis B Silver; Joseph J Mattapallil; Reiko Horai; Zaruhi Karabekian; J Hugh McDowell; Chi-Chao Chan; Eddie A James; William W Kwok; H Nida Sen; Robert B Nussenblatt; Chella S David; Rachel R Caspi
Journal:  J Immunol       Date:  2011-07-15       Impact factor: 5.422

4.  High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids.

Authors:  Viviane M Sakata; Felipe T da Silva; Carlos E Hirata; Maria Lucia C Marin; Helcio Rodrigues; Jorge Kalil; Rogerio A Costa; Joyce H Yamamoto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-16       Impact factor: 3.117

5.  HLA-DRB1 among patients with Vogt-Koyanagi-Harada disease in Saudi Arabia.

Authors:  Alia Iqniebi; Ameera Gaafar; Atia Sheereen; Abdullah Al-Suliman; Gamal Mohamed; Khaled Al-Hussein; Khalid F Tabbara
Journal:  Mol Vis       Date:  2009-09-12       Impact factor: 2.367

6.  A shared HLA-DRB1 epitope in the DR beta first domain is associated with Vogt-Koyanagi-Harada syndrome in Indian patients.

Authors:  Jean-Marie Tiercy; Sivakumar R Rathinam; Marianne Gex-Fabry; Edoardo Baglivo
Journal:  Mol Vis       Date:  2010-03-05       Impact factor: 2.367

7.  Frequent immune response to a melanocyte specific protein KU-MEL-1 in patients with Vogt-Koyanagi-Harada disease.

Authors:  S Otani; T Sakurai; K Yamamoto; T Fujita; Y Matsuzaki; Y Goto; Y Ando; S Suzuki; M Usui; M Takeuchi; Y Kawakami
Journal:  Br J Ophthalmol       Date:  2006-02-15       Impact factor: 4.638

8.  A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice.

Authors:  Giuseppina Pennesi; Mary J Mattapallil; Shu-Hui Sun; Dody Avichezer; Phyllis B Silver; Zaruhi Karabekian; Chella S David; Paul A Hargrave; J Hugh McDowell; W Clay Smith; Barbara Wiggert; Larry A Donoso; Chi-Chao Chan; Rachel R Caspi
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

9.  Genome-wide association analysis of Vogt-Koyanagi-Harada syndrome identifies two new susceptibility loci at 1p31.2 and 10q21.3.

Authors:  Shengping Hou; Liping Du; Bo Lei; Chi Pui Pang; Meifen Zhang; Wenjuan Zhuang; Minglian Zhang; Lulin Huang; Bo Gong; Meilin Wang; Qi Zhang; Ke Hu; Qingyun Zhou; Jian Qi; Chaokui Wang; Yuan Tian; Zi Ye; Liang Liang; Hongsong Yu; Hong Li; Yan Zhou; Qingfeng Cao; Yunjia Liu; Lin Bai; Dan Liao; Aize Kijlstra; Jianfeng Xu; Zhenglin Yang; Peizeng Yang
Journal:  Nat Genet       Date:  2014-08-10       Impact factor: 38.330

10.  Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up.

Authors:  Sabine Aisenbrey; Christoph Lüke; Helen D Ayertey; Salvatore Grisanti; Andreas Perniok; Richard Brunner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-14       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.